Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

Cancer discovery - 1 Jan 2016

Russo Mariangela, Misale Sandra, Wei Ge, Siravegna Giulia, Crisafulli Giovanni, Lazzari Luca, Corti Giorgio, Rospo Giuseppe, Novara Luca, Mussolin Benedetta, Bartolini Alice, Cam Nicholas, Patel Roopal, Yan Shunqi, Shoemaker Robert, Wild Robert, Di Nicolantonio Federica, Bianchi Andrea Sartore, Li Gang, Siena Salvatore, Bardelli Alberto

Abstract excerpt

UNLABELLED: Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clinical testing in colorectal cancer and other tumor types. A patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance. To characterize the molecular bases of the patient's relapse,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Catalytic Domain

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gene Rearrangement

Share to Indazoles

Share to Neoplasm Transplantation

Share to Neoplastic Cells, Circulating

Share to Receptor, trkA

Source

Identifiers

PMID: 26546295
DOI: 10.1158/2159-8290.CD-15-0940

Genes

NTRK1
LMNA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.PMID 26546295Read ↗

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerSemantic proximity Read ↗

TRK Inhibition: A New Tumor-Agnostic Treatment StrategySemantic proximity Read ↗

Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.Semantic proximity Read ↗

Targeting TRK: A Fast Tracked Application of Precision Oncology and Future DirectionsSemantic proximity Read ↗

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read ↗

TRKing down an old oncogene in a new era of targeted therapy.Semantic proximity Read ↗

Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion CancerSemantic proximity Read ↗

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.Semantic proximity Read ↗

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasmsSemantic proximity Read ↗

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.Semantic proximity Read ↗

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.